ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2443

A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis

P. Sarzi-Puttini1, F. Atzeni1, Luigi Lanata2, Alessandra Monguzzi2 and Michela Bagnasco2, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2Medical Department, Dompé SpA, Milan, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: meta-analysis, pain management and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ARHP): Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for management of mild-to-moderate pain, chronic inflammatory and degenerative joint diseases. Among NSAIDs, ketoprofen, ibuprofen and diclofenac have been widely used for the last 30 years and particular attention should be taken into account when choosing a NSAIDs in order to achieve the best risk/benefit ratio for patients. Recent publication of our comparative meta-analysis demonstrating that efficacy of oral ketoprofen is greater than ibuprofen and/or diclofenac, raised many questions about safety profile of these molecules. For this reason we performed this meta-analysis of randomised controlled trials (RCTs) in order to compare the safety of orally administered ketoprofen vs ibuprofen and diclofenac and to obtain a complete comparative assessment of risk/benefit profile of these NSAIDs.

Methods: A systematic literature search was performed on main databases (Medline, Cochrane Central and Embase) until July 2013 to identify RCTs comparing directly therapeutic doses of oral ketoprofen (50-200 mg/day) vs ibuprofen (600-1800 mg/day) or diclofenac (75-150 mg/day). In accordance with the Cochrane Collaboration guideline, two rheumatologists carried out independently study selection.

Results: A total of 10 RCTs involving 826 patients met the inclusion criteria. Five of the 10 RCTs included patients with systemic rheumatic diseases. Findings from this meta-analysis did not reveal any difference in safety for ketoprofen compared to ibuprofen and/or diclofenac. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was not statistically significant (risk ratio; RR=1.02, 95% CI 0.78-1.33; P=0.92) at all point-estimates of the mean weighted size effect. Further sub-analysis also confirmed that ketoprofen was not significantly different to either diclofenac (RR=0.86; 95% CI 0.51-1.45; P=0.58) or ibuprofen (RR=1.08; 95% CI 0.79-1.48; P=0.65) at all point-estimates. Heterogeneity for the safety measures analysed were not statistically significant for all meta-analyses.

Conclusion : Findings of this meta-analysis show that ketoprofen is well tolerated, with a safety profile at least comparable to ibuprofen and diclofenac, and no serious AEs. In light of superior efficacy demonstrated in our previous meta-analysis, these further safety results support recommendation that oral ketoprofen has the best risk/benefit profile vs ibuprofen and diclofenac.


Disclosure:

P. Sarzi-Puttini,
None;

F. Atzeni,
None;

L. Lanata,

Dompè SpA,

3;

A. Monguzzi,

Dompè SpA,

3;

M. Bagnasco,

Dompè SpA,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-new-meta-analysis-on-safety-of-ketoprofen-vs-ibuprofen-and-diclofenac-risk-and-benefit-of-nsaids-beyond-efficacy-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology